Proceedings from a CME symposium held at the 2020 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Crystal Denlinger, Howard S Hochster, John L Marshall, Michael J Overman, Philip A Philip and Prof Eric Van Cutsem. <ul> <li>Introduction — Dr Neil Love (00:00)</li> <li>The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers — Dr Hochster (16:20)</li> <li>Lingering Questions in the Selection and Sequence of Therapy for Patients with mCRC — Dr Marshall (44:23)</li> <li>Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Overman (1:05:39)</li> <li>Optimal Management of Metastatic Gastric/Gastroesophageal Cancer — Dr Denlinger (1:33:29)</li> <li>Contemporary Treatment Approaches for Patients with Pancreatic Cancer — Dr Philip (1:53:28)</li> <li>PARP Inhibition in Pancreatic Cancer; Promising Investigational Strategies — Prof Van Cutsem (2:15:15)</li> </ul> <a href= "http://m.researchtopractice.com/GICancers20/PanTumor?playlistIndex=0#t=0m0s"> CME information and select publications</a>

Proceedings from a CME symposium held at the 2020 Gastrointestinal Cancers Symposium. Featuring perspectives from Drs Crystal Denlinger, Howard S Hochster, John L Marshall, Michael J Overman, Philip A Philip and Prof Eric Van Cutsem. Introduction — Dr Neil Love (00:00) The Emergence of Targeted Therapy for Patients with Metastatic Colorectal Cancer (mCRC) and BRAF V600E Tumor Mutations; HER2 and Other Potential Biomarkers — Dr Hochster (16:20) Lingering Questions in the Selection and Sequence of Therapy for Patients with mCRC — Dr Marshall (44:23) Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC — Dr Overman (1:05:39) Optimal Management of Metastatic Gastric/Gastroesophageal Cancer — Dr Denlinger (1:33:29) Contemporary Treatment Approaches for Patients with Pancreatic Cancer — Dr Philip (1:53:28) PARP Inhibition in Pancreatic Cancer; Promising Investigational Strategies — Prof Van Cutsem (2:15:15) CME information and select publications

Research To Practice | Oncology Videos

Colorectal, Gastroesophageal and Pancreatic Cancer | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Colorectal, Gastroesophageal and Pancreatic Cancer

Featuring perspectives from Dr Shirish M Gadgeel on the later-line management of metastatic squamous cell carcinoma of the lung. <ul> <li>Recent advances in the management of advanced non-small cell lung cancer (NSCLC) (0:00)</li> <li>Case: A woman in her early 70s with metastatic squamous cell carcinoma (SCC) of the lung receives carboplatin/paclitaxel and pembrolizumab as first-line therapy on the KEYNOTE-021 trial (02:25)</li> <li>Response to pembrolizumab and chemotherapy in advanced SCC of the lung (04:34)</li> <li>Efficacy of pembrolizumab alone or in combination with chemotherapy for advanced NSCLC (07:41)</li> <li>Choice of immune checkpoint inhibitor/chemotherapy regimen as first-line therapy for metastatic SCC of the lung (12:22)</li> <li>Results of the Phase III CheckMate 227 trial evaluating nivolumab alone, with ipilimumab or with chemotherapy as first-line therapy for metastatic NSCLC (15:43)</li> <li>Interim overall survival analysis of the Phase III IMpower110 study investigating atezolizumab versus platinum-based chemotherapy for metastatic NSCLC in the first-line setting (18:32)</li> <li>Cancer site and adverse events induced by immune checkpoint inhibitors (20:05)</li> <li>Genetic alterations in patients with SCC of the lung; rationale for targeting the ERBB signaling pathway (22:18)</li> <li>Results of the Phase III LUX-Lung 8 trial of afatinib versus erlotinib as second-line treatment for advanced SCC of the lung (25:53)</li> <li>Secondary analysis of LUX-Lung 8: Association of ERBB mutations with clinical outcomes among patients with afatinib- or erlotinib-treated SCC of the lung (28:04)</li> <li>Role of HER2 mutations and HER2 amplification in patients with NSCLC; incidence of HER2 alterations in patients with SCC of the lung (30:14)</li> <li>Targeting HER2 alterations with the tyrosine kinase inhibitors afatinib and dacomitinib in patients with NSCLC (34:15)</li> <li>Efficacy of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201) in patients with NSCLC and HER2 alterations (36:11)</li> <li>Activity of T-DM1 in patients with NSCLC and HER2 mutations (38:04)</li> <li>Management of gastrointestinal side effects associated with afatinib (40:22)</li> <li>Activity of afatinib in heavily pretreated ERBB2 mutation-positive advanced NSCLC (43:01)</li> <li>Afatinib in patients with metastatic or recurrent lung cancer with HER2 mutations  (45:15)</li> <li>Case: A man in his early 80s develops metastases to the liver during treatment with durvalumab after chemoradiation therapy for Stage III SCC of the lung and is found to have FGFR1 amplification (47:15)</li> <li>FGFR signaling as a target for NSCLC therapy; outcomes with the FGFR inhibitor AZD4547 in patients with metastatic SCC of the lung and FGFR alterations (51:04)</li> <li>SWOG-S1400 Lung Cancer Master Protocol (Lung-MAP) — Biomarker-targeted therapy for patients with previously treated Stage IV SCC of the lung (56:02)</li> <li>Case: A woman in her early 50s with ALK-rearranged metastatic lung adenocarcinoma experiences a dramatic response to crizotinib on the PROFILE 1014 study (1:02:39)</li> <li>Response to ALK inhibitors for ALK-rearranged metastatic NSCLC (1:06:54)</li> </ul> <a href= "http://m.researchtopractice.com/iJournalClub20/Video?playlistIndex=0#t=0m0s"> CME information and select publications</a>

Featuring perspectives from Dr Shirish M Gadgeel on the later-line management of metastatic squamous cell carcinoma of the lung. Recent advances in the management of advanced non-small cell lung cancer (NSCLC) (0:00) Case: A woman in her early 70s with metastatic squamous cell carcinoma (SCC) of the lung receives carboplatin/paclitaxel and pembrolizumab as first-line therapy on the KEYNOTE-021 trial (02:25) Response to pembrolizumab and chemotherapy in advanced SCC of the lung (04:34) Efficacy of pembrolizumab alone or in combination with chemotherapy for advanced NSCLC (07:41) Choice of immune checkpoint inhibitor/chemotherapy regimen as first-line therapy for metastatic SCC of the lung (12:22) Results of the Phase III CheckMate 227 trial evaluating nivolumab alone, with ipilimumab or with chemotherapy as first-line therapy for metastatic NSCLC (15:43) Interim overall survival analysis of the Phase III IMpower110 study investigating atezolizumab versus platinum-based chemotherapy for metastatic NSCLC in the first-line setting (18:32) Cancer site and adverse events induced by immune checkpoint inhibitors (20:05) Genetic alterations in patients with SCC of the lung; rationale for targeting the ERBB signaling pathway (22:18) Results of the Phase III LUX-Lung 8 trial of afatinib versus erlotinib as second-line treatment for advanced SCC of the lung (25:53) Secondary analysis of LUX-Lung 8: Association of ERBB mutations with clinical outcomes among patients with afatinib- or erlotinib-treated SCC of the lung (28:04) Role of HER2 mutations and HER2 amplification in patients with NSCLC; incidence of HER2 alterations in patients with SCC of the lung (30:14) Targeting HER2 alterations with the tyrosine kinase inhibitors afatinib and dacomitinib in patients with NSCLC (34:15) Efficacy of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201) in patients with NSCLC and HER2 alterations (36:11) Activity of T-DM1 in patients with NSCLC and HER2 mutations (38:04) Management of gastrointestinal side effects associated with afatinib (40:22) Activity of afatinib in heavily pretreated ERBB2 mutation-positive advanced NSCLC (43:01) Afatinib in patients with metastatic or recurrent lung cancer with HER2 mutations  (45:15) Case: A man in his early 80s develops metastases to the liver during treatment with durvalumab after chemoradiation therapy for Stage III SCC of the lung and is found to have FGFR1 amplification (47:15) FGFR signaling as a target for NSCLC therapy; outcomes with the FGFR inhibitor AZD4547 in patients with metastatic SCC of the lung and FGFR alterations (51:04) SWOG-S1400 Lung Cancer Master Protocol (Lung-MAP) — Biomarker-targeted therapy for patients with previously treated Stage IV SCC of the lung (56:02) Case: A woman in her early 50s with ALK-rearranged metastatic lung adenocarcinoma experiences a dramatic response to crizotinib on the PROFILE 1014 study (1:02:39) Response to ALK inhibitors for ALK-rearranged metastatic NSCLC (1:06:54) CME information and select publications

Lung Cancer | iJournal Club: Later-Line Therapy for Patients with Metastatic Squamous Cell Carcinoma of the Lung

Proceedings from a roundtable discussion with Drs Courtney D DiNardo, Keith W Pratz, Richard M Stone and a group of 20 general medical oncologists and nurse practitioners on the optimal management of acute myeloid leukemia within a community-based setting. <ul> <li>Initial Workup and Determination of Eligibility for Intensive Treatment; Integrating Venetoclax into the Treatment of Acute Myeloid Leukemia (AML)</li> <li style="list-style: none; display: inline;"> <ul> <li>Faculty presentation — Dr DiNardo: Exploring the current management paradigm for AML in patients not eligible for intensive therapy (00:00)</li> <li>Case (Dr Marte): A woman in her early 80s who presented 7 years ago with t(8;21) AML is in complete remission 7 years after treatment with 7+3 chemotherapy (09:13)</li> <li>Therapeutic options for older patients with AML without targetable mutations (11:02)</li> <li>Genetic testing for patients with AML (16:21)</li> <li>Assessment of minimal residual disease status in patients undergoing treatment for AML; selection of patients who are eligible for intensive chemotherapy (19:40)</li> <li>Choice of therapy for a patient with AML and multiple comorbidities (23:36)</li> <li>Prophylaxis for patients receiving venetoclax in combination with azacitidine (26:57)</li> <li>Optimal duration of venetoclax therapy (29:05)</li> <li>Prevention and management of tumor lysis syndrome associated with venetoclax (30:58)</li> <li>Selection of therapy for a patient with AML with complex karyotype and a TP53 mutation (34:58)</li> <li>Case (Dr Dandamudi): A woman in her early 80s with AML attains an excellent response to venetoclax and azacitidine (38:11)</li> <li>Case (Dr Choksi): A woman in her late 70s with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm develops neutropenia after treatment with venetoclax and azacitidine (43:13)</li> <li>Case (Dr Hussein): A man in his early 80s develops persistent neutropenia after receiving azacitidine for MDS, which resolves after treatment with pembrolizumab for metastatic melanoma (51:14)</li> <li>Choice of hypomethylating agent for patients with AML (52:42)</li> <li>Case (Dr Gandhi): A man in his mid-70s with AML receives venetoclax/decitabine (55:34)</li> <li>Perspective on the use of GCSF for the management of neutropenia associated with venetoclax/azacitidine for AML (57:49)</li> </ul> </li> <li>Management of AML with FLT3 and IDH Mutations</li> <li style="list-style: none; display: inline;"> <ul> <li>Faculty presentation — Dr Stone: Management of AML with a FLT3 mutation in older patients who are not eligible for intensive treatment (1:00:36)</li> <li>Therapeutic approach for elderly patients with FLT3-ITD AML and high allelic burden (1:08:08)</li> <li>Case (Ms Sanchez): A woman in her mid-60s with FLT3-ITD AML is enrolled on a clinical trial evaluating gilteritinib as maintenance therapy after allogeneic transplant (1:11:48)</li> <li>Activity and tolerability of gilteritinib and sorafenib in patients with AML (1:16:39)</li> <li>Ongoing investigation of venetoclax in combination with a hypomethylating agent for younger/fit patients with AML (1:19:26)</li> <li>Duration of response to therapy with venetoclax and a hypomethylating agent; investigation of approaches to overcome resistance (1:22:31)</li> <li>Case (Dr Sullivan): A man in his mid-30s with AML with mutations in FLT3, MPN1 and ROS1 experiences disease progression after chemotherapy and FLT3 inhibitors (1:24:46)</li> <li>Case (Dr Dandamudi): A man in his early 70s receives venetoclax and azacitidine for AML (1:32:43)</li> <li>Faculty presentation — Dr Pratz:Therapeutic approach for older patients with AML with IDH1/2 mutations who are not eligible for intensive treatment (1:35:52)</li> <li>Selection of first-line therapy for patients with AML with an IDH mutation (1:45:08)</li> <li>Side effects associated with ivosidenib; management of differentiation syndrome related to IDH inhibitors (1:48:41)</li> <li>Case (Dr Shah): A man in his late 80s with AML with an IDH2 mutation and multiple comorbidities receives enasidenib (1:54:41)</li> <li>Case (Dr Malhotra): A man in his early 60s with AML with an IDH2 mutation receives enasidenib (1:57:56)</li> </ul> </li> </ul> <a href="http://m.researchtopractice.com/AML20">CME information and select publications</a>

Proceedings from a roundtable discussion with Drs Courtney D DiNardo, Keith W Pratz, Richard M Stone and a group of 20 general medical oncologists and nurse practitioners on the optimal management of acute myeloid leukemia within a community-based setting. Initial Workup and Determination of Eligibility for Intensive Treatment; Integrating Venetoclax into the Treatment of Acute Myeloid Leukemia (AML) Faculty presentation — Dr DiNardo: Exploring the current management paradigm for AML in patients not eligible for intensive therapy (00:00) Case (Dr Marte): A woman in her early 80s who presented 7 years ago with t(8;21) AML is in complete remission 7 years after treatment with 7+3 chemotherapy (09:13) Therapeutic options for older patients with AML without targetable mutations (11:02) Genetic testing for patients with AML (16:21) Assessment of minimal residual disease status in patients undergoing treatment for AML; selection of patients who are eligible for intensive chemotherapy (19:40) Choice of therapy for a patient with AML and multiple comorbidities (23:36) Prophylaxis for patients receiving venetoclax in combination with azacitidine (26:57) Optimal duration of venetoclax therapy (29:05) Prevention and management of tumor lysis syndrome associated with venetoclax (30:58) Selection of therapy for a patient with AML with complex karyotype and a TP53 mutation (34:58) Case (Dr Dandamudi): A woman in her early 80s with AML attains an excellent response to venetoclax and azacitidine (38:11) Case (Dr Choksi): A woman in her late 70s with myelodysplastic syndrome (MDS)/myeloproliferative neoplasm develops neutropenia after treatment with venetoclax and azacitidine (43:13) Case (Dr Hussein): A man in his early 80s develops persistent neutropenia after receiving azacitidine for MDS, which resolves after treatment with pembrolizumab for metastatic melanoma (51:14) Choice of hypomethylating agent for patients with AML (52:42) Case (Dr Gandhi): A man in his mid-70s with AML receives venetoclax/decitabine (55:34) Perspective on the use of GCSF for the management of neutropenia associated with venetoclax/azacitidine for AML (57:49) Management of AML with FLT3 and IDH Mutations Faculty presentation — Dr Stone: Management of AML with a FLT3 mutation in older patients who are not eligible for intensive treatment (1:00:36) Therapeutic approach for elderly patients with FLT3-ITD AML and high allelic burden (1:08:08) Case (Ms Sanchez): A woman in her mid-60s with FLT3-ITD AML is enrolled on a clinical trial evaluating gilteritinib as maintenance therapy after allogeneic transplant (1:11:48) Activity and tolerability of gilteritinib and sorafenib in patients with AML (1:16:39) Ongoing investigation of venetoclax in combination with a hypomethylating agent for younger/fit patients with AML (1:19:26) Duration of response to therapy with venetoclax and a hypomethylating agent; investigation of approaches to overcome resistance (1:22:31) Case (Dr Sullivan): A man in his mid-30s with AML with mutations in FLT3, MPN1 and ROS1 experiences disease progression after chemotherapy and FLT3 inhibitors (1:24:46) Case (Dr Dandamudi): A man in his early 70s receives venetoclax and azacitidine for AML (1:32:43) Faculty presentation — Dr Pratz:Therapeutic approach for older patients with AML with IDH1/2 mutations who are not eligible for intensive treatment (1:35:52) Selection of first-line therapy for patients with AML with an IDH mutation (1:45:08) Side effects associated with ivosidenib; management of differentiation syndrome related to IDH inhibitors (1:48:41) Case (Dr Shah): A man in his late 80s with AML with an IDH2 mutation and multiple comorbidities receives enasidenib (1:54:41) Case (Dr Malhotra): A man in his early 60s with AML with an IDH2 mutation receives enasidenib (1:57:56) CME information and select publications

Acute Myeloid Leukemia | Exploring Current Management Paradigms for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Therapy

Lung Cancer Update, Issue 1, 2020: Our interview with Dr Ko highlights the following topics as well as cases from his practice: <ul> <li>Case: A man in his mid-50s with metastatic non-small cell lung cancer (NSCLC) and an ALK rearrangement receives brigatinib as first-line therapy on the ALTA-1L trial (00:00)</li> <li>Results from the Phase III ALTA-1L and ALEX studies evaluating brigatinib or alectinib versus crizotinib for patients with advanced NSCLC and an ALK rearrangement (02:33)</li> <li>Side effects, dosing and quality of life with alectinib and brigatinib (06:51)</li> <li>Early onset pulmonary events associated with brigatinib (08:47)</li> <li>Activity of lorlatinib as second- or third-line therapy for NSCLC with an ALK rearrangement (11:39)</li> <li>Targeting the MET pathway for patients with NSCLC who experience disease progression on EGFR and ALK inhibitors (14:15)</li> <li>Treatment for patients with metastatic NSCLC and an ALK rearrangement who experience disease progression on an ALK inhibitor (17:01)</li> <li>Perspective on the potential identification of patients who might experience rapid disease progression on ALK inhibitors (19:26)</li> <li>Role of immune checkpoint inhibitors for patients with metastatic NSCLC and targetable mutations (22:51)</li> <li>PD-L1 expression as a predictive biomarker for patients with actionable alterations; approach to the use of immunotherapy (26:03)</li> <li>Treatment for patients with metastatic NSCLC and EGFR mutations who have experienced disease progression after targeted therapy (28:40)</li> <li>Case: A woman in her early 50s with metastatic NSCLC and an EGFR exon 20 insertion experiences disease progression after treatment with TAK-788 and whole-brain radiation therapy (32:22)</li> <li>Perspective on dementia associated with whole-brain radiation therapy (35:10)</li> <li>Guidelines from the Response Assessment in Neuro-Oncology Brain Metastases working group: Clinical trial design for systemic agents for brain metastases (39:27)</li> <li>Hippocampus sparing during radiation therapy for brain metastases (41:08)</li> <li>Targeting EGFR exon 20 insertions with TAK-788 and poziotinib (42:40)</li> <li>Incidence of NTRK alterations and treatment for patients with NTRK alterations (46:22)</li> <li>Case: A man in his mid-60s, a heavy smoker, with metastatic squamous cell lung carcinoma and MET amplification receives carboplatin/paclitaxel/pembrolizumab as first-line therapy (48:51)</li> <li>Choice of chemotherapy for patients with metastatic squamous cell lung cancer and targetable alterations (52:16)</li> <li>Efficacy of the selective MET inhibitors tepotinib and capmatinib for patients with advanced NSCLC and MET exon 14 skipping mutations (53:56)</li> <li>Prognosis and treatment for patients with NSCLC and KRAS mutations (57:37)</li> <li>Predictors of benefit with immunotherapy for patients with NSCLC (59:39)</li> <li>Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies for NSCLC (1:00:55)</li> </ul> <a href="http://m.researchtopractice.com/LCU120/Video">CME information and select publications</a>

Lung Cancer Update, Issue 1, 2020: Our interview with Dr Ko highlights the following topics as well as cases from his practice: Case: A man in his mid-50s with metastatic non-small cell lung cancer (NSCLC) and an ALK rearrangement receives brigatinib as first-line therapy on the ALTA-1L trial (00:00) Results from the Phase III ALTA-1L and ALEX studies evaluating brigatinib or alectinib versus crizotinib for patients with advanced NSCLC and an ALK rearrangement (02:33) Side effects, dosing and quality of life with alectinib and brigatinib (06:51) Early onset pulmonary events associated with brigatinib (08:47) Activity of lorlatinib as second- or third-line therapy for NSCLC with an ALK rearrangement (11:39) Targeting the MET pathway for patients with NSCLC who experience disease progression on EGFR and ALK inhibitors (14:15) Treatment for patients with metastatic NSCLC and an ALK rearrangement who experience disease progression on an ALK inhibitor (17:01) Perspective on the potential identification of patients who might experience rapid disease progression on ALK inhibitors (19:26) Role of immune checkpoint inhibitors for patients with metastatic NSCLC and targetable mutations (22:51) PD-L1 expression as a predictive biomarker for patients with actionable alterations; approach to the use of immunotherapy (26:03) Treatment for patients with metastatic NSCLC and EGFR mutations who have experienced disease progression after targeted therapy (28:40) Case: A woman in her early 50s with metastatic NSCLC and an EGFR exon 20 insertion experiences disease progression after treatment with TAK-788 and whole-brain radiation therapy (32:22) Perspective on dementia associated with whole-brain radiation therapy (35:10) Guidelines from the Response Assessment in Neuro-Oncology Brain Metastases working group: Clinical trial design for systemic agents for brain metastases (39:27) Hippocampus sparing during radiation therapy for brain metastases (41:08) Targeting EGFR exon 20 insertions with TAK-788 and poziotinib (42:40) Incidence of NTRK alterations and treatment for patients with NTRK alterations (46:22) Case: A man in his mid-60s, a heavy smoker, with metastatic squamous cell lung carcinoma and MET amplification receives carboplatin/paclitaxel/pembrolizumab as first-line therapy (48:51) Choice of chemotherapy for patients with metastatic squamous cell lung cancer and targetable alterations (52:16) Efficacy of the selective MET inhibitors tepotinib and capmatinib for patients with advanced NSCLC and MET exon 14 skipping mutations (53:56) Prognosis and treatment for patients with NSCLC and KRAS mutations (57:37) Predictors of benefit with immunotherapy for patients with NSCLC (59:39) Ongoing investigation of anti-PD-1/PD-L1 and anti-CTLA-4 antibodies for NSCLC (1:00:55) CME information and select publications

Lung Cancer | D Ross Camidge, MD, PhD

A presentation on breast cancer featuring perspectives from Dr Sara Hurvitz. <ul> <li>Introduction (00:00)</li> <li>Chemotherapy with Immunotherapy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (00:53)</li> <li>T-DM1 for Residual HER2-Positive Disease After Neoadjuvant Therapy (12:17)</li> <li>PARP Inhibitors in Metastatic Breast Cancer (19:37)</li> <li>PI3 Kinase Inhibitors in Hormone Receptor-Positive Metastatic Disease (26:47)</li> <li>Novel HER2-Directed Investigational Approaches (34:15)</li> </ul> <a href= "http://m.researchtopractice.com/GrandRoundsBreast20/References">CME information and select publications</a>

A presentation on breast cancer featuring perspectives from Dr Sara Hurvitz. Introduction (00:00) Chemotherapy with Immunotherapy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (00:53) T-DM1 for Residual HER2-Positive Disease After Neoadjuvant Therapy (12:17) PARP Inhibitors in Metastatic Breast Cancer (19:37) PI3 Kinase Inhibitors in Hormone Receptor-Positive Metastatic Disease (26:47) Novel HER2-Directed Investigational Approaches (34:15) CME information and select publications

Breast Cancer | Visiting Professors: Investigator Perspectives on Recently Approved and Emerging Strategies in the Management of Breast Cancer

A special video supplement to a CME conference held during the 2019 San Antonio Breast Cancer Symposium featuring expert comments on the management of ER-positive breast cancer. Featuring perspectives from Dr Harold J Burstein. <ul> <li>Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer (00:00)</li> <li>Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer (03:23)</li> <li>Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer (05:27)</li> <li>Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality (10:42)</li> <li>NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI) (12:28)</li> <li>Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance (14:56)</li> <li>Management of de novo ER-positive, HER2-negative mBC (18:22)</li> <li>Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC (21:39)</li> <li>Approach for patients with mBC and disease progression on an AI (24:04)</li> <li>Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles (26:40)</li> <li>Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC (31:35)</li> <li>Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role (33:27)</li> <li>Spectrum, frequency and severity of toxicities observed with alpelisib (36:09)</li> <li>Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor (39:07)</li> <li>Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC (40:54)</li> <li>Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC (44:00)</li> <li>Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC (46:40)</li> <li>Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway (50:06)</li> <li>Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role (51:08)</li> <li>Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher (56:40)</li> <li>Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer (1:02:24)</li> </ul> <a href= "http://m.researchtopractice.com/SanAntonioBC19/ER/Interview/Video?playlistIndex=0#t=0m0s"> CME information and select publications</a>

A special video supplement to a CME conference held during the 2019 San Antonio Breast Cancer Symposium featuring expert comments on the management of ER-positive breast cancer. Featuring perspectives from Dr Harold J Burstein. Use of genomic classifiers to inform therapeutic decision-making for ER-positive localized breast cancer (00:00) Prognostic and/or predictive utility of the various genomic assays for patients with node-negative and node-positive early breast cancer (03:23) Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized breast cancer (05:27) Effects of prolonging adjuvant aromatase inhibitor therapy beyond 5 years on recurrence and cause-specific mortality (10:42) NSABP-B-42: Ten-year results of extended adjuvant endocrine therapy with letrozole for postmenopausal women with ER-positive breast cancer who have completed previous adjuvant therapy with an aromatase inhibitor (AI) (12:28) Optimizing the use of CDK4/6 inhibitors in the management of ER-positive metastatic breast cancer (mBC); overall survival findings and mechanisms of resistance (14:56) Management of de novo ER-positive, HER2-negative mBC (18:22) Choice of endocrine therapy partner for patients with de novo ER-positive, HER2-negative mBC (21:39) Approach for patients with mBC and disease progression on an AI (24:04) Selection and sequencing of CDK4/6 inhibitors in mBC; comparison of side-effect profiles (26:40) Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC (31:35) Results of the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with ER-positive, HER2-negative advanced BC with or without a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval for breast cancer with a PIK3CA mutation and current clinical role (33:27) Spectrum, frequency and severity of toxicities observed with alpelisib (36:09) Clinical experience with everolimus in mBC; potential for its use after disease progression on a CDK4/6 inhibitor (39:07) Biologic rationale for evaluation of the Bcl-2 inhibitor venetoclax in ER-positive mBC (40:54) Overview of the novel HER2-directed agents trastuzumab deruxtecan and tucatinib for HER2-positive mBC (44:00) Dual targeted approach for patients with ER/PR-positive, HER2-positive mBC (46:40) Investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway (50:06) Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role (51:08) Perspectives of Dr Burstein and Dr Love on the passing and legacy of the breast cancer revolutionary Dr Bernard Fisher (56:40) Advances in the adjuvant treatment of HER2-positive and triple-negative breast cancer (1:02:24) CME information and select publications

ER-Positive Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer — A Special Video Supplement

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Harold J Burstein, Dr Matthew Goetz, Prof Stephen RD Johnston and Dr Joseph A Sparano. Introduction <ul> <li>Program Overview: Dr Love (00:00)</li> <li>Use of Genomic Classifiers to Inform Therapeutic Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC)</li> <li>Case (Dr Goetz): A premenopausal woman in her early 40s with a 1.4-cm, ER-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 9 (1:14)</li> <li>Case (Prof Johnston): A woman in her late 30s with a 1.8-cm, ER-positive, HER2-negative, node-negative IDC and an intermediate 21-gene Recurrence Score (9:24)</li> <li>Case (Dr Burstein): A woman in her late 50s with a 1.3-cm, ER-positive, HER2-negative IDC and 1 positive sentinel lymph node (11:11)</li> <li>Faculty Presentation: Dr Sparano (13:57)</li> <li>Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive Metastatic BC (mBC)</li> <li>Case (Dr Goetz): A woman in her mid-40s develops liver and bone metastases near the completion of 5 years of letrozole for ER-positive BC (34:52)</li> <li>Faculty Presentation: Dr Goetz (38:28)</li> <li>Case (Dr Sparano): A man in his late 40s presents with de novo ER-positive, HER2-negative mBC to the lung and bones and receives abemaciclib and tamoxifen (51:17)</li> <li>Current and Future Management of ER-Positive mBC After Disease Progression on CDK4/6 Inhibition</li> <li>Case (Dr Sparano): A woman in her early 40s with ER-positive, HER2-negative mBC who has experienced disease progression on multiple lines of endocrine therapy is found to have a PIK3CA mutation (56:48)</li> <li>Case (Dr Goetz): A woman in her mid-40s receives abemaciclib/fulvestrant for ER-positive, HER2-negative mBC but experiences disease progression after 2 years (57:32)</li> <li>Faculty Presentation: Dr Burstein (1:00:03)</li> <li>Novel Applications of CDK4/6 Inhibitors; Ongoing Clinical Trials</li> <li>Faculty Presentation: Prof Johnston (1:16:55)</li> <li>Case (Prof Johnston): A woman in her mid-30s who has experienced disease progression on multiple lines of therapy, including most recently palbociclib/fulvestrant, undergoes multiplex testing, which reveals ESR1 and PIK3CA mutations (1:30:49)</li> </ul> <a href="http://m.researchtopractice.com/SanAntonioBC19/ER">CME information and select publications</a>

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Harold J Burstein, Dr Matthew Goetz, Prof Stephen RD Johnston and Dr Joseph A Sparano. Introduction Program Overview: Dr Love (00:00) Use of Genomic Classifiers to Inform Therapeutic Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC) Case (Dr Goetz): A premenopausal woman in her early 40s with a 1.4-cm, ER-positive, HER2-negative, node-negative IDC and a 21-gene Recurrence Score® of 9 (1:14) Case (Prof Johnston): A woman in her late 30s with a 1.8-cm, ER-positive, HER2-negative, node-negative IDC and an intermediate 21-gene Recurrence Score (9:24) Case (Dr Burstein): A woman in her late 50s with a 1.3-cm, ER-positive, HER2-negative IDC and 1 positive sentinel lymph node (11:11) Faculty Presentation: Dr Sparano (13:57) Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive Metastatic BC (mBC) Case (Dr Goetz): A woman in her mid-40s develops liver and bone metastases near the completion of 5 years of letrozole for ER-positive BC (34:52) Faculty Presentation: Dr Goetz (38:28) Case (Dr Sparano): A man in his late 40s presents with de novo ER-positive, HER2-negative mBC to the lung and bones and receives abemaciclib and tamoxifen (51:17) Current and Future Management of ER-Positive mBC After Disease Progression on CDK4/6 Inhibition Case (Dr Sparano): A woman in her early 40s with ER-positive, HER2-negative mBC who has experienced disease progression on multiple lines of endocrine therapy is found to have a PIK3CA mutation (56:48) Case (Dr Goetz): A woman in her mid-40s receives abemaciclib/fulvestrant for ER-positive, HER2-negative mBC but experiences disease progression after 2 years (57:32) Faculty Presentation: Dr Burstein (1:00:03) Novel Applications of CDK4/6 Inhibitors; Ongoing Clinical Trials Faculty Presentation: Prof Johnston (1:16:55) Case (Prof Johnston): A woman in her mid-30s who has experienced disease progression on multiple lines of therapy, including most recently palbociclib/fulvestrant, undergoes multiplex testing, which reveals ESR1 and PIK3CA mutations (1:30:49) CME information and select publications

ER-Positive Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Drs Adam M Brufsky, Lisa A Carey, Sara Hurvitz and Martine J Piccart-Gebhart. <ul> <li>Introduction</li> <li style="list-style: none; display: inline;"> <ul> <li>Program Overview: Dr Love (00:00)</li> </ul> </li> <li>Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Brufsky): A woman in her mid-30s with an ER-positive, HER2-positive, node-negative IDC receives neoadjuvant TCHP and at surgery is found to have residual disease in the breast (10:40)</li> <li>Case (Dr Carey): A woman in her mid-80s with a large ER-positive, HER2-positive, node-positive IDC has difficulty tolerating neoadjuvant therapy and has a small amount of residual disease in the breast at surgery (13:10)</li> <li>Faculty Presentation: Dr Carey (16:53)</li> </ul> </li> <li>Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Brufsky): A woman in her early 60s with a 1.5-cm, ER-positive, HER2-positive IDC and 3 positive sentinel nodes (30:51)</li> <li>Case (Dr Carey): A woman in her mid-40s with ER-negative, HER2-positive, node-negative BC receives adjuvant T-DM1 on the ATTEMPT trial (36:54)</li> <li>Faculty Presentation: Dr Piccart-Gebhart (42:11)</li> </ul> </li> <li>Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC)</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Hurvitz): A woman in her early 60s with HER2-positive mBC to the liver achieves a complete response to THP → HP but develops CNS metastases 3 years later (52:43)</li> <li>Case (Dr Piccart-Gebhart): A woman in her late 30s with heavily pretreated ER-positive, HER2-positive mBC receives neratinib/letrozole (55:07)</li> <li>Faculty Presentation: Dr Brufsky (57:51)</li> </ul> </li> <li>Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Hurvitz): A woman in her late 40s with ER-positive, HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after disease progression on multiple lines of therapy (1:09:56)</li> </ul> </li> <li>Case (Dr Piccart-Gebhart): A woman in her late 20s receives multiple lines of local and systemic therapy for ER-positive, HER2-positive mBC (1:11:29)</li> <li>Faculty Presentation: Dr Hurvitz (1:13:41)</li> </ul> <a href= "http://m.researchtopractice.com/SanAntonioBC19/HER2">CME information and select publications</a>

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Drs Adam M Brufsky, Lisa A Carey, Sara Hurvitz and Martine J Piccart-Gebhart. Introduction Program Overview: Dr Love (00:00) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer (BC) Receiving Neoadjuvant Systemic Therapy Case (Dr Brufsky): A woman in her mid-30s with an ER-positive, HER2-positive, node-negative IDC receives neoadjuvant TCHP and at surgery is found to have residual disease in the breast (10:40) Case (Dr Carey): A woman in her mid-80s with a large ER-positive, HER2-positive, node-positive IDC has difficulty tolerating neoadjuvant therapy and has a small amount of residual disease in the breast at surgery (13:10) Faculty Presentation: Dr Carey (16:53) Adjuvant and Extended-Adjuvant Therapy for Patients with Localized HER2-Positive BC Case (Dr Brufsky): A woman in her early 60s with a 1.5-cm, ER-positive, HER2-positive IDC and 3 positive sentinel nodes (30:51) Case (Dr Carey): A woman in her mid-40s with ER-negative, HER2-positive, node-negative BC receives adjuvant T-DM1 on the ATTEMPT trial (36:54) Faculty Presentation: Dr Piccart-Gebhart (42:11) Available Therapeutic Options for the Management of HER2-Positive Metastatic BC (mBC) Case (Dr Hurvitz): A woman in her early 60s with HER2-positive mBC to the liver achieves a complete response to THP → HP but develops CNS metastases 3 years later (52:43) Case (Dr Piccart-Gebhart): A woman in her late 30s with heavily pretreated ER-positive, HER2-positive mBC receives neratinib/letrozole (55:07) Faculty Presentation: Dr Brufsky (57:51) Novel Agents and Strategies Under Evaluation for Patients with HER2-Positive mBC Case (Dr Hurvitz): A woman in her late 40s with ER-positive, HER2-positive mBC receives trastuzumab deruxtecan on a clinical trial after disease progression on multiple lines of therapy (1:09:56) Case (Dr Piccart-Gebhart): A woman in her late 20s receives multiple lines of local and systemic therapy for ER-positive, HER2-positive mBC (1:11:29) Faculty Presentation: Dr Hurvitz (1:13:41) CME information and select publications

HER2-Positive Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of HER2-Positive Breast Cancer

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Erika Hamilton, Prof Sherene Loi, Dr Mark E Robson and Dr Hope S Rugo. <ul> <li>Introduction</li> <li style="list-style: none; display: inline;"> <ul> <li>Program Overview: Dr Love (00:00)</li> </ul> </li> <li>Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Loi): A woman in her early 40s with PD-L1-positive metastatic TNBC (mTNBC) and a germline BRCA mutation (01:11)</li> <li>Case (Dr Robson): A woman in her early 40s with PD-L1-positive mTNBC experiences disease progression on atezolizumab/nab paclitaxel and is considering next steps (09:29)</li> <li>Faculty Presentation: Dr Hamilton (14:16)</li> </ul> </li> <li>Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Hamilton): A woman in her mid-50s with mTNBC achieves a complete response to atezolizumab/nab paclitaxel on the IMpassion130 trial (26:59)</li> <li>Faculty Presentation: Dr Rugo (34:22)</li> </ul> </li> <li>Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC         </li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Rugo): A woman in her early 30s with TNBC and a BRCA1 mutation has extensive residual disease after neoadjuvant chemotherapy and receives olaparib (54:25)</li> <li>Case (Dr Hamilton): A woman in her early 60s with mTNBC and a germline BRCA2 mutation experiences gastrointestinal toxicities and cytopenias while receiving olaparib (56:28)</li> <li>Faculty Presentation: Dr Robson (58:34)</li> </ul> </li> <li>Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials</li> <li style="list-style: none; display: inline;"> <ul> <li>Case (Dr Rugo): A woman in her late 50s with TNBC experiences prolonged stable disease after receiving adjuvant capecitabine followed by pembrolizumab (1:11:49)</li> <li>Case (Dr Robson): A woman in her early 40s initially diagnosed with TNBC and a germline BRCA mutation presents 8 years later with node-positive contralateral TNBC (1:14:53)</li> <li>Faculty Presentation: Prof Loi (1:19:45)</li> </ul> </li> </ul> <a href= "http://m.researchtopractice.com/SanAntonioBC19/TNBC">CME information and select publications</a>

Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Erika Hamilton, Prof Sherene Loi, Dr Mark E Robson and Dr Hope S Rugo. Introduction Program Overview: Dr Love (00:00) Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making Case (Dr Loi): A woman in her early 40s with PD-L1-positive metastatic TNBC (mTNBC) and a germline BRCA mutation (01:11) Case (Dr Robson): A woman in her early 40s with PD-L1-positive mTNBC experiences disease progression on atezolizumab/nab paclitaxel and is considering next steps (09:29) Faculty Presentation: Dr Hamilton (14:16) Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC Case (Dr Hamilton): A woman in her mid-50s with mTNBC achieves a complete response to atezolizumab/nab paclitaxel on the IMpassion130 trial (26:59) Faculty Presentation: Dr Rugo (34:22) Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC          Case (Dr Rugo): A woman in her early 30s with TNBC and a BRCA1 mutation has extensive residual disease after neoadjuvant chemotherapy and receives olaparib (54:25) Case (Dr Hamilton): A woman in her early 60s with mTNBC and a germline BRCA2 mutation experiences gastrointestinal toxicities and cytopenias while receiving olaparib (56:28) Faculty Presentation: Dr Robson (58:34) Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials Case (Dr Rugo): A woman in her late 50s with TNBC experiences prolonged stable disease after receiving adjuvant capecitabine followed by pembrolizumab (1:11:49) Case (Dr Robson): A woman in her early 40s initially diagnosed with TNBC and a germline BRCA mutation presents 8 years later with node-positive contralateral TNBC (1:14:53) Faculty Presentation: Prof Loi (1:19:45) CME information and select publications

Triple-Negative Breast Cancer | Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer

Acute Leukemias Update, Issue 1, 2020 — Part 1: Our interview with Dr Perl highlights the following topics as well as cases from his practice: <ul> <li>Case: A woman in her early 70s with a history of triple-negative breast cancer receives venetoclax/azacitidine for secondary acute myeloid leukemia (AML) (00:00)</li> <li>Nonspecific symptoms of AML at initial diagnosis (02:11)</li> <li>Efficacy and safety of liposomal cytarabine/daunorubicin (CPX-351) in older patients with newly diagnosed AML (04:02)</li> <li>Essential diagnostic workup and genetic testing in AML: Consideration of disease characteristics in treatment decision-making (06:09)</li> <li>Differentiating therapy-related AML; treatment outcomes in patients with unfavorable, complex or monosomal karyotypes (09:25)</li> <li>Prior treatments that increase the risk of therapy-related AML; factors to consider in selecting intensive versus nonintensive treatment for therapy-related disease (11:48)</li> <li>Considering patient needs and preferences in choosing intensive versus nonintensive treatment (16:15)</li> <li>Potential cure rates for patients with AML in different clinical scenarios (20:05)</li> <li>Diagnostic workup for AML; importance of genetic alterations in treatment selection (23:05)</li> <li>Workup for intermediate- or favorable-risk karyotypes to guide the decision to use gemtuzumab ozogamicin in AML (27:11)</li> <li>Integrating the FDA reapproved agent gemtuzumab ozogamicin into therapy for AML: Outcomes from the Phase III ALFA-0701 trial (29:10)</li> <li>Role of the hedgehog inhibitor glasdegib in front-line therapy for patients with AML not eligible for intensive induction chemotherapy (30:44)</li> <li>Treatment of AML with venetoclax and a hypomethylating agent: Considerations for optimizing therapeutic benefit (33:57)</li> <li>Prevention of tumor lysis syndrome in patients with AML receiving venetoclax-based therapy (36:03)</li> <li>Efficacy of front-line venetoclax/azacitidine for AML (37:36)</li> <li>Age- and fitness-based risk-benefit assessment when determining whether to administer venetoclax/azacitidine to patients with AML (42:08)</li> <li>Monitoring for and mitigation of tumor lysis syndrome associated with venetoclax/azacitidine (43:59)</li> <li>Management of myelosuppression associated with venetoclax in combination with a hypomethylating agent (47:08)</li> <li>Case: A man in his mid-20s presents with hyperplasia, leukocytosis and fatigue and is diagnosed with AML with a FLT3 mutation (49:24)</li> <li>Efficacy and safety results from the Phase III ADMIRAL trial of gilteritinib for relapsed or refractory AML; potential for moving gilteritinib into earlier lines of therapy (53:44)</li> <li>FLT3 inhibitors as maintenance therapy: Optimal duration, quality of life and the ongoing Phase III BMT CTN 1506 trial (58:30)</li> <li>Outcomes with gilteritinib as front-line therapy for AML with a FLT3 mutation (1:01:49)</li> <li>Treatment options for older patients with AML with FLT3 mutations who are not candidates for intensive therapy (1:03:48)</li> <li>Evidence supporting the use of IDH inhibitors for older patients with AML with IDH1/2 mutations (1:09:22)</li> <li>Evolving treatment landscape in acute lymphoblastic leukemia (ALL); management paradigm for ALL in younger versus older patients or those with Philadelphia chromosome-positive disease (1:13:02)</li> <li>Efficacy and safety of the bispecific T-cell engager blinatumomab as a salvage therapy option for relapsed or refractory ALL (1:18:34)</li> <li>Chimeric antigen receptor (CAR) T-cell therapies in the third-line setting for patients with relapsed or refractory ALL: Efficacy outcomes and tolerability (1:22:18)</li> <li>FDA approval of tisagenlecleucel for ALL; perspective on improving T-cell persistence and overcoming resistance to CAR T-cell therapy (1:25:29)</li> </ul> <a href= "http://m.researchtopractice.com/AcuteLeukemiasUpdate120/Video">CME information and select publications</a>

Acute Leukemias Update, Issue 1, 2020 — Part 1: Our interview with Dr Perl highlights the following topics as well as cases from his practice: Case: A woman in her early 70s with a history of triple-negative breast cancer receives venetoclax/azacitidine for secondary acute myeloid leukemia (AML) (00:00) Nonspecific symptoms of AML at initial diagnosis (02:11) Efficacy and safety of liposomal cytarabine/daunorubicin (CPX-351) in older patients with newly diagnosed AML (04:02) Essential diagnostic workup and genetic testing in AML: Consideration of disease characteristics in treatment decision-making (06:09) Differentiating therapy-related AML; treatment outcomes in patients with unfavorable, complex or monosomal karyotypes (09:25) Prior treatments that increase the risk of therapy-related AML; factors to consider in selecting intensive versus nonintensive treatment for therapy-related disease (11:48) Considering patient needs and preferences in choosing intensive versus nonintensive treatment (16:15) Potential cure rates for patients with AML in different clinical scenarios (20:05) Diagnostic workup for AML; importance of genetic alterations in treatment selection (23:05) Workup for intermediate- or favorable-risk karyotypes to guide the decision to use gemtuzumab ozogamicin in AML (27:11) Integrating the FDA reapproved agent gemtuzumab ozogamicin into therapy for AML: Outcomes from the Phase III ALFA-0701 trial (29:10) Role of the hedgehog inhibitor glasdegib in front-line therapy for patients with AML not eligible for intensive induction chemotherapy (30:44) Treatment of AML with venetoclax and a hypomethylating agent: Considerations for optimizing therapeutic benefit (33:57) Prevention of tumor lysis syndrome in patients with AML receiving venetoclax-based therapy (36:03) Efficacy of front-line venetoclax/azacitidine for AML (37:36) Age- and fitness-based risk-benefit assessment when determining whether to administer venetoclax/azacitidine to patients with AML (42:08) Monitoring for and mitigation of tumor lysis syndrome associated with venetoclax/azacitidine (43:59) Management of myelosuppression associated with venetoclax in combination with a hypomethylating agent (47:08) Case: A man in his mid-20s presents with hyperplasia, leukocytosis and fatigue and is diagnosed with AML with a FLT3 mutation (49:24) Efficacy and safety results from the Phase III ADMIRAL trial of gilteritinib for relapsed or refractory AML; potential for moving gilteritinib into earlier lines of therapy (53:44) FLT3 inhibitors as maintenance therapy: Optimal duration, quality of life and the ongoing Phase III BMT CTN 1506 trial (58:30) Outcomes with gilteritinib as front-line therapy for AML with a FLT3 mutation (1:01:49) Treatment options for older patients with AML with FLT3 mutations who are not candidates for intensive therapy (1:03:48) Evidence supporting the use of IDH inhibitors for older patients with AML with IDH1/2 mutations (1:09:22) Evolving treatment landscape in acute lymphoblastic leukemia (ALL); management paradigm for ALL in younger versus older patients or those with Philadelphia chromosome-positive disease (1:13:02) Efficacy and safety of the bispecific T-cell engager blinatumomab as a salvage therapy option for relapsed or refractory ALL (1:18:34) Chimeric antigen receptor (CAR) T-cell therapies in the third-line setting for patients with relapsed or refractory ALL: Efficacy outcomes and tolerability (1:22:18) FDA approval of tisagenlecleucel for ALL; perspective on improving T-cell persistence and overcoming resistance to CAR T-cell therapy (1:25:29) CME information and select publications

Acute Leukemias | Alexander Perl, MD

Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice: <ul> <li>Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00)</li> <li>Molecular profiling in the diagnosis and treatment of AML (01:54)</li> <li>Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14)</li> <li>CPX-351 for secondary AML (07:16)</li> <li>Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45)</li> <li>Clinical experience with and tolerability of gilteritinib (16:12)</li> <li>Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54)</li> <li>Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17)</li> <li>Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50)</li> <li>Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01)</li> <li>Activity and safety of immune checkpoint inhibitors in patients with AML (32:58)</li> <li>Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06)</li> <li>Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32)</li> <li>Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22)</li> <li>Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15)</li> <li>Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56)</li> <li>Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23)</li> <li>Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33)</li> <li>Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17)</li> <li>Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34)</li> <li>Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19)</li> <li>Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44)</li> <li>Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51)</li> </ul> <a href= "http://m.researchtopractice.com/AcuteLeukemiasUpdate120/Video">CME information and select publications</a>

Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice: Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00) Molecular profiling in the diagnosis and treatment of AML (01:54) Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14) CPX-351 for secondary AML (07:16) Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45) Clinical experience with and tolerability of gilteritinib (16:12) Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54) Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17) Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50) Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01) Activity and safety of immune checkpoint inhibitors in patients with AML (32:58) Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06) Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32) Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22) Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15) Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56) Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23) Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33) Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17) Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34) Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19) Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44) Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51) CME information and select publications

Acute Leukemias | Eunice Wang, MD

Proceedings from Part 1 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Dr Jeremy Abramson, Dr Bruce D Cheson, Prof John G Gribben, Dr Brad S Kahl, Dr Loretta Nastoupil and Dr Laurie H Sehn. <ul> <li>Introduction</li> <li style="list-style: none; display: inline"> <ul> <li>Program Overview: Dr Love (00:00)</li> </ul> </li> <li>Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL)</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Khan): A man in his late 40s with IGHV-mutated CLL who achieves a complete remission with first-line FCR but experiences multiple toxicities (01:26)</li> <li>Case (Dr Peswani): A man in his late 70s who presents with highly symptomatic CLL requiring an immediate response to treatment (10:36)</li> <li>Faculty Presentation: Dr Kahl (18:19)</li> </ul> </li> <li>Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Kale): A woman in her late 70s with small lymphocytic lymphoma who is hospitalized for the initial cycles of venetoclax/obinutuzumab because of poor renal function (31:50)</li> <li>Case (Dr Lamar): A man in his early 70s with CLL who receives ibrutinib and develops atrial fibrillation and hematuria requiring dose reduction (39:25)</li> <li>Faculty Presentation: Prof Gribben (46:38)</li> </ul> </li> <li>Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL)</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Kale): A man in his mid-70s with Stage III FL and multiple comorbidities who experiences a prolonged response to rituximab monotherapy (1:00:14)</li> <li>Additional questions from the community oncologist/hematologist panel regarding the management of FL (1:03:34)</li> <li>Faculty Presentation: Dr Cheson (1:12:05)</li> </ul> </li> <li>Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL)</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Peswani): A man in his early 70s who is diagnosed with MCL with gastrointestinal involvement (1:24:13)</li> <li>Additional questions from the community oncologist/hematologist panel regarding the management of MCL (1:28:31)</li> <li>Faculty Presentation: Dr Abramson (1:33:51)</li> </ul> </li> <li>Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Brenner): A woman in her mid-80s with DLBCL and a performance status of 2 who receives R-mini-CHOP but experiences disease progression after 4 months (1:47:02)</li> <li>Case (Dr Morganstein): A man in his early 60s with triple-hit DLBCL (1:52:35)</li> <li>Faculty Presentation: Dr Sehn (1:55:18)</li> </ul> </li> <li>Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas</li> <li style="list-style: none; display: inline"> <ul> <li>Questions from the community oncologist/hematologist panel regarding CAR T-cell therapy (2:08:34)</li> <li>Case (Dr Morganstein): A man in his early 40s with DLBCL who receives CAR T-cell therapy after no response to up-front R-CHOP and disease progression after salvage chemotherapy followed by ASCT (2:13:19)</li> <li>Faculty Presentation: Dr Nastoupil (2:16:08)</li> </ul> </li> </ul> <a href="http://m.researchtopractice.com/ASHNHL19">CME information and select publications</a>

Proceedings from Part 1 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Dr Jeremy Abramson, Dr Bruce D Cheson, Prof John G Gribben, Dr Brad S Kahl, Dr Loretta Nastoupil and Dr Laurie H Sehn. Introduction Program Overview: Dr Love (00:00) Evolving Therapeutic Algorithms for Patients with Treatment-Naïve Chronic Lymphocytic Leukemia (CLL) Case (Dr Khan): A man in his late 40s with IGHV-mutated CLL who achieves a complete remission with first-line FCR but experiences multiple toxicities (01:26) Case (Dr Peswani): A man in his late 70s who presents with highly symptomatic CLL requiring an immediate response to treatment (10:36) Faculty Presentation: Dr Kahl (18:19) Management of Relapsed/Refractory (R/R) CLL and Novel Investigational Approaches Case (Dr Kale): A woman in her late 70s with small lymphocytic lymphoma who is hospitalized for the initial cycles of venetoclax/obinutuzumab because of poor renal function (31:50) Case (Dr Lamar): A man in his early 70s with CLL who receives ibrutinib and develops atrial fibrillation and hematuria requiring dose reduction (39:25) Faculty Presentation: Prof Gribben (46:38) Contemporary Management of Newly Diagnosed and R/R Follicular Lymphoma (FL) Case (Dr Kale): A man in his mid-70s with Stage III FL and multiple comorbidities who experiences a prolonged response to rituximab monotherapy (1:00:14) Additional questions from the community oncologist/hematologist panel regarding the management of FL (1:03:34) Faculty Presentation: Dr Cheson (1:12:05) Protocol and Off-Protocol Care for Patients with Mantle Cell Lymphoma (MCL) Case (Dr Peswani): A man in his early 70s who is diagnosed with MCL with gastrointestinal involvement (1:24:13) Additional questions from the community oncologist/hematologist panel regarding the management of MCL (1:28:31) Faculty Presentation: Dr Abramson (1:33:51) Recent Breakthroughs and Other Promising Approaches in the Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) Case (Dr Brenner): A woman in her mid-80s with DLBCL and a performance status of 2 who receives R-mini-CHOP but experiences disease progression after 4 months (1:47:02) Case (Dr Morganstein): A man in his early 60s with triple-hit DLBCL (1:52:35) Faculty Presentation: Dr Sehn (1:55:18) Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Lymphomas Questions from the community oncologist/hematologist panel regarding CAR T-cell therapy (2:08:34) Case (Dr Morganstein): A man in his early 40s with DLBCL who receives CAR T-cell therapy after no response to up-front R-CHOP and disease progression after salvage chemotherapy followed by ASCT (2:13:19) Faculty Presentation: Dr Nastoupil (2:16:08) CME information and select publications

Lymphomas and Chronic Lymphocytic Leukemia | Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia

Proceedings from Part 2 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Drs Jesús G Berdeja, Sagar Lonial, María-Victoria Mateos, Nikhil C Munshi, Robert Z Orlowski and Noopur Raje. <ul> <li>Introduction</li> <li style="list-style: none; display: inline"> <ul> <li>Program Overview: Dr Love  (00:00)</li> </ul> </li> <li>Up-Front Management of Multiple Myeloma (MM)</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Peswani): A woman in her early 70s who achieves a VGPR to induction RVd but is unwilling to undergo ASCT (01:08)</li> <li>Case (Dr Khan): A woman in her mid-80s with IgG lambda MM and poor renal function (07:00)</li> <li>Faculty Presentation: Dr Raje (20:51)</li> </ul> </li> <li>Consolidation and Maintenance Therapy; Emerging Role of Minimal Residual Disease</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Brenner): A man in his early 50s with Stage III IgG lambda MM and t(14;16) (33:39)</li> <li>Case (Dr Lamar): A woman in her late 70s presents with renal failure, is diagnosed with MM and receives CyBorD (38:01)</li> <li>Faculty Presentation: Dr Munshi (43:40)</li> </ul> </li> <li>Current Management of Relapsed/Refractory MM</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Brenner): A man in his late 60s experiences a biochemical relapse while receiving lenalidomide maintenance after RVd and ASCT (59:22)</li> <li>Additional questions from the community oncologist/hematologist panel regarding the management of relapsed/refractory MM (1:02:22)</li> <li>Faculty Presentation: Dr Mateos (1:06:40)</li> </ul> </li> <li>Novel Strategies Under Investigation for the Treatment of MM</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Brenner): A man in his late 80s with t(11;14) MM and multiple comorbidities experiences disease progression on second-line pomalidomide/daratumumab/dexamethasone (1:19:25)</li> <li>Faculty Presentation: Dr Lonial (1:21:52)</li> </ul> </li> <li>Therapeutic Strategies Targeting B-Cell Maturation Antigen in MM</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Lamar): A man in his late 40s with high-risk MM experiences rapid disease progression on RVd (1:39:10)</li> <li>Faculty Presentation: Dr Berdeja (1:42:24)</li> </ul> </li> <li>Amyloidosis and Waldenström Macroglobulinemia (WM)</li> <li style="list-style: none; display: inline"> <ul> <li>Case (Dr Khan): A woman in her late 50s with multiple comorbidities is diagnosed with renal amyloidosis and receives up-front CyBorD (2:08:32)</li> <li>Case (Dr Lamar): A fit man in his early 90s who has been observed for 4 to 5 years for WM (2:14:02)</li> <li>Faculty Presentation: Dr Orlowski (2:17:28)</li> </ul> </li> </ul> <a href="http://m.researchtopractice.com/ASHMM19">CME information and select publications</a>

Proceedings from Part 2 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Drs Jesús G Berdeja, Sagar Lonial, María-Victoria Mateos, Nikhil C Munshi, Robert Z Orlowski and Noopur Raje. Introduction Program Overview: Dr Love  (00:00) Up-Front Management of Multiple Myeloma (MM) Case (Dr Peswani): A woman in her early 70s who achieves a VGPR to induction RVd but is unwilling to undergo ASCT (01:08) Case (Dr Khan): A woman in her mid-80s with IgG lambda MM and poor renal function (07:00) Faculty Presentation: Dr Raje (20:51) Consolidation and Maintenance Therapy; Emerging Role of Minimal Residual Disease Case (Dr Brenner): A man in his early 50s with Stage III IgG lambda MM and t(14;16) (33:39) Case (Dr Lamar): A woman in her late 70s presents with renal failure, is diagnosed with MM and receives CyBorD (38:01) Faculty Presentation: Dr Munshi (43:40) Current Management of Relapsed/Refractory MM Case (Dr Brenner): A man in his late 60s experiences a biochemical relapse while receiving lenalidomide maintenance after RVd and ASCT (59:22) Additional questions from the community oncologist/hematologist panel regarding the management of relapsed/refractory MM (1:02:22) Faculty Presentation: Dr Mateos (1:06:40) Novel Strategies Under Investigation for the Treatment of MM Case (Dr Brenner): A man in his late 80s with t(11;14) MM and multiple comorbidities experiences disease progression on second-line pomalidomide/daratumumab/dexamethasone (1:19:25) Faculty Presentation: Dr Lonial (1:21:52) Therapeutic Strategies Targeting B-Cell Maturation Antigen in MM Case (Dr Lamar): A man in his late 40s with high-risk MM experiences rapid disease progression on RVd (1:39:10) Faculty Presentation: Dr Berdeja (1:42:24) Amyloidosis and Waldenström Macroglobulinemia (WM) Case (Dr Khan): A woman in her late 50s with multiple comorbidities is diagnosed with renal amyloidosis and receives up-front CyBorD (2:08:32) Case (Dr Lamar): A fit man in his early 90s who has been observed for 4 to 5 years for WM (2:14:02) Faculty Presentation: Dr Orlowski (2:17:28) CME information and select publications

Multiple Myeloma, Amyloidosis and Waldenström Macroglobulinemia | Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenström Macroglobulinemia

Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases: Our most recent one-on-one interview with Dr Riely as a supplement to a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology featuring expert comments on the application of emerging research to patient care. <ul> <li>Improved treatment outcomes and impact on the incidence of brain metastases in patients with non-small cell lung cancer (NSCLC) (00:00)</li> <li>Case (Dr Gubens): A man in his mid-50s with adenocarcinoma of the lung with an EGFR exon 19 deletion mutation, asymptomatic brain lesions and significant systemic burden (03:43)</li> <li>Clinical care of patients with NSCLC brain metastases alone and no systemic disease (06:23)</li> <li>Diagnosis of radiation necrosis (11:42)</li> <li>Activity of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib in patients with NSCLC and CNS metastases (13:17)</li> <li>Mechanism of action of osimertinib in the brain and effect on CNS disease progression (15:43)</li> <li>Risks of whole-brain radiation therapy; role of hippocampus sparing and memantine administration in minimizing the adverse effects of whole-brain radiation therapy (17:42)</li> <li>Comparison of survival outcomes with stereotactic radiation therapy and EGFR TKIs (22:24)</li> <li>Case (Dr Gubens): A man in his late 40s with metastatic NSCLC with an ALK rearrangement and large asymptomatic brain metastases (24:46)</li> <li>Role of other TKIs (ie, BRAF, MET, HER2 inhibitors) in NSCLC with CNS metastases (28:15)</li> <li>Antitumor effect of ALK inhibitors in patients with CNS metastases (31:58)</li> <li>Practical issues in the management of CNS metastases: edema, symptomatic CNS metastases and oligoprogression (33:21)</li> <li>Managing CNS metastases with leptomeningeal involvement (36:44)</li> <li>Case (Dr Gubens): A man in his early 40s with metastatic adenocarcinoma of the lung with an EGFR L858R mutation responds to first-line osimertinib for 2 years but then develops 2 new asymptomatic punctate parenchymal metastases and extensive leptomeningeal involvement (39:01)</li> <li>Symptoms of CNS metastases with leptomeningeal involvement; challenges in diagnosis (43:13)</li> <li>Case (Dr Gubens): A woman in her late 60s with metastatic adenocarcinoma of the lung, no targetable tumor mutations and a PD-L1 tumor proportion score (TPS) of 80% (44:53)</li> <li>Outlook on the use of TKIs for patients with CNS metastases (48:42)</li> <li>Potential for combining TKIs with chemotherapy in the management of CNS metastases (50:19)</li> <li>Activity and safety of EGFR TKIs in combination with anti-PD-1/PD-L1 antibodies (52:14)</li> </ul> <a href= "http://m.researchtopractice.com/SNO19/Interview/Video">CME information and select publications</a>

Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases: Our most recent one-on-one interview with Dr Riely as a supplement to a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology featuring expert comments on the application of emerging research to patient care. Improved treatment outcomes and impact on the incidence of brain metastases in patients with non-small cell lung cancer (NSCLC) (00:00) Case (Dr Gubens): A man in his mid-50s with adenocarcinoma of the lung with an EGFR exon 19 deletion mutation, asymptomatic brain lesions and significant systemic burden (03:43) Clinical care of patients with NSCLC brain metastases alone and no systemic disease (06:23) Diagnosis of radiation necrosis (11:42) Activity of the third-generation EGFR tyrosine kinase inhibitor (TKI) osimertinib in patients with NSCLC and CNS metastases (13:17) Mechanism of action of osimertinib in the brain and effect on CNS disease progression (15:43) Risks of whole-brain radiation therapy; role of hippocampus sparing and memantine administration in minimizing the adverse effects of whole-brain radiation therapy (17:42) Comparison of survival outcomes with stereotactic radiation therapy and EGFR TKIs (22:24) Case (Dr Gubens): A man in his late 40s with metastatic NSCLC with an ALK rearrangement and large asymptomatic brain metastases (24:46) Role of other TKIs (ie, BRAF, MET, HER2 inhibitors) in NSCLC with CNS metastases (28:15) Antitumor effect of ALK inhibitors in patients with CNS metastases (31:58) Practical issues in the management of CNS metastases: edema, symptomatic CNS metastases and oligoprogression (33:21) Managing CNS metastases with leptomeningeal involvement (36:44) Case (Dr Gubens): A man in his early 40s with metastatic adenocarcinoma of the lung with an EGFR L858R mutation responds to first-line osimertinib for 2 years but then develops 2 new asymptomatic punctate parenchymal metastases and extensive leptomeningeal involvement (39:01) Symptoms of CNS metastases with leptomeningeal involvement; challenges in diagnosis (43:13) Case (Dr Gubens): A woman in her late 60s with metastatic adenocarcinoma of the lung, no targetable tumor mutations and a PD-L1 tumor proportion score (TPS) of 80% (44:53) Outlook on the use of TKIs for patients with CNS metastases (48:42) Potential for combining TKIs with chemotherapy in the management of CNS metastases (50:19) Activity and safety of EGFR TKIs in combination with anti-PD-1/PD-L1 antibodies (52:14) CME information and select publications

Lung Cancer and CNS Metastases| Gregory J Riely, MD, PhD

Proceedings from a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology. Featuring perspectives from moderator Dr Matthew Gubens and faculty members Drs Manmeet S Ahluwalia, Daniel Gomez and Gregory J Riely: <ul> <li>Prevalence and Clinical Significance of Central Nervous System (CNS) Involvement in Non-Small Cell Lung Cancer (NSCLC); Indications for Various Local Treatment Modalities — Dr Gomez (00:00)</li> <li>Optimal Management of Brain Metastases in Oncogene-Driven NSCLC — Dr Riely (9:23)</li> <li>Management of Leptomeningeal Metastases in NSCLC with a Targetable Tumor Mutation; Role of Immune Checkpoint Inhibition in the Treatment of CNS Disease Stemming from NSCLC — Dr Ahluwalia (19:59)</li> </ul> <a href="http://m.researchtopractice.com/SNO19">CME information and select publications</a>

Proceedings from a CME symposium held during the 24th Annual Meeting and Education Day of the Society for Neuro-Oncology. Featuring perspectives from moderator Dr Matthew Gubens and faculty members Drs Manmeet S Ahluwalia, Daniel Gomez and Gregory J Riely: Prevalence and Clinical Significance of Central Nervous System (CNS) Involvement in Non-Small Cell Lung Cancer (NSCLC); Indications for Various Local Treatment Modalities — Dr Gomez (00:00) Optimal Management of Brain Metastases in Oncogene-Driven NSCLC — Dr Riely (9:23) Management of Leptomeningeal Metastases in NSCLC with a Targetable Tumor Mutation; Role of Immune Checkpoint Inhibition in the Treatment of CNS Disease Stemming from NSCLC — Dr Ahluwalia (19:59) CME information and select publications

NSCLC | Consensus or Controversy? The Integration of Novel Therapies into the Interdisciplinary Management of Non-Small Cell Lung Cancer with CNS Metastases

Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.

hubhopper

Research To Practice | Oncology Videos

hubhopper